Suppr超能文献

联合检测血清人组织激肽释放酶和 CA-125 对上皮性卵巢癌的检测。

Combined panel of serum human tissue kallikreins and CA-125 for the detection of epithelial ovarian cancer.

机构信息

Department of Obstetrics and Gynaecology, National University Health System (NUHS), Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

出版信息

J Gynecol Oncol. 2012 Jul;23(3):175-81. doi: 10.3802/jgo.2012.23.3.175. Epub 2012 Jul 2.

Abstract

OBJECTIVE

To determine the predictive accuracy of the combined panels of serum human tissue kallikreins (hKs) and CA-125 for the detection of epithelial ovarian cancer.

METHODS

Serum specimens collected from 5 Indonesian centers and 1 Vietnamese center were analyzed for CA-125, hK6, and hK10 levels. A total of 375 specimens from patients presenting with ovarian tumors, which include 156 benign cysts, 172 epithelial ovarian cancers (stage I/II, n=72; stage III/IV, n=100), 36 germ cell tumors and 11 borderline tumors, were included in the study analysis. Receiver operating characteristic analysis were performed to determine the cutoffs for age, CA-125, hK6, and hK10. Sensitivity, specificity, negative, and positive predictive values were determined for various combinations of the biomarkers.

RESULTS

The levels of hK6 and hK10 were significantly elevated in ovarian cancer cases compared to benign cysts. Combination of 3 markers, age/CA-125/hk6 or CA-125/hk6/hk10, showed improved specificity (100%) and positive predictive value (100%) for prediction of ovarian cancer, when compared to the performance of single markers having 80-92% specificity and 74-87% positive predictive value. Four-marker combination, age/CA-125/hK6/hK10 also showed 100% specificity and 100% positive predictive value, although it demonstrated low sensitivity (11.9%) and negative predictive value (52.8%).

CONCLUSION

The combination of human tissue kallikreins and CA-125 showed potential for improving prediction of epithelial ovarian cancer in patients presenting with ovarian tumors.

摘要

目的

确定血清人组织激肽释放酶(hKs)和 CA-125 联合检测对上皮性卵巢癌的预测准确性。

方法

分析来自印尼 5 个中心和越南 1 个中心的血清标本中 CA-125、hK6 和 hK10 的水平。共纳入 375 例卵巢肿瘤患者的标本,包括 156 例良性囊肿、172 例上皮性卵巢癌(I/II 期,n=72;III/IV 期,n=100)、36 例生殖细胞肿瘤和 11 例交界性肿瘤。进行受试者工作特征分析,以确定年龄、CA-125、hK6 和 hK10 的截断值。确定各种生物标志物组合的敏感性、特异性、阴性预测值和阳性预测值。

结果

与良性囊肿相比,卵巢癌患者的 hK6 和 hK10 水平显著升高。与具有 80-92%特异性和 74-87%阳性预测值的单一标志物相比,年龄/CA-125/hk6 或 CA-125/hk6/hk10 三种标志物的组合显示出更好的特异性(100%)和阳性预测值(100%),用于预测卵巢癌。四种标志物的组合,年龄/CA-125/hK6/hK10 也显示出 100%的特异性和 100%的阳性预测值,尽管其敏感性(11.9%)和阴性预测值(52.8%)较低。

结论

人组织激肽释放酶和 CA-125 的联合检测具有改善卵巢肿瘤患者上皮性卵巢癌预测的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2a3/3395013/2d043c56c468/jgo-23-175-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验